Penicillin-Induced Anti-Factor VIII Antibodies: A Case Report

نویسندگان

چکیده

Introduction: Acquired hemophilia A is very rare autoimmune disorder caused by an autoantibody to factor VIII that interferes with its coagulant function. It may be associated a number of conditions such as lymphoproliferative disorders, drugs and solid malignancies. Hemarthrosis in clinical presentation was never reported cases induced penicillin. Case presentation: We report 65-year-old male, born living Brazil, who presented hemorrhagic episodes complicated joint hemarthrosis due acquired commonly used drug, Benzathine penicillin.Disease management focused on controlling bleeding, primarily the use inhibition bypassing activity eradicate using various immunosuppressants. The challenges manage this case included delayed diagnosis, durable remissions, difficulty achieving hemostasis. Clinical laboratory coagulation response has improved eight weeks after only administration double immunosuppression medication: corticosteroid cyclophosphamide. Conclusion: This gives us lesson prompt diagnosis treatment achieved hematologists improve prognosis prevent severe bleeding. Early detection vital improving outcomes.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case.

Daily administration of large doses of factor VIII concentrate in a hemophiliac with a high titer factor VIII inhibitor resulted in marked reduction in the titer and response of the inhibitor to factor VIII administration and made possible elbow and bilateral knee replacements under conventional factor VIII coverage. Studies performed during the course of treatment indicated that the reduction ...

متن کامل

Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

One major obstacle in gene therapy is the generation of immune responses directed against transgene product. Five consecutive anti-CD3 treatments concomitant with factor VIII (FVIII) plasmid injection prevented the formation of inhibitory antibodies against FVIII and achieved persistent, therapeutic levels of FVIII gene expression in treated hemophilia A mice. Repeated plasmid gene transfer is ...

متن کامل

Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.

This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the...

متن کامل

Quantitation of anti-factor VIII antibodies in human plasma.

The presence of antibodies (Abs) in hemophilia A patients can potentially influence the therapeutic qualities of factor VIII (fVIII) administration. Much work has been focused on the presence of inhibitory antibodies, whereas the quantitation of noninhibitory anti-fVIII antibodies has been largely undetermined. Our objective was to develop a sensitive and specific fluorescence-based immunoassay...

متن کامل

Characterization of a monoclonal anti-idiotype antibody to human anti-factor VIII antibodies.

Approximately 15% of individuals with hemophilia A develop antibodies (inhibitors) to therapeutically infused factor VIII that interfere with F.VIII coagulant activity. By using isoelectric focusing and immunospecific detection of anti-factor VIII antibodies, inhibitor plasma showed varied patterns of reactivity characteristic of a polyclonal response. Inhibitor plasma from patient Bt was obser...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Medical research archives

سال: 2023

ISSN: ['2375-1916', '2375-1924']

DOI: https://doi.org/10.18103/mra.v11i4.3529